CD8A and neoplasm: In another preclinical study, a human papillomavirus (HPV) therapeutic vaccine in combination with NHS-IL12 controlled the tumor growth of an HPV+ murine tumor, which was associated with the expansion of activated CD8+ T cell population in the TME (137).